Bergen, Norway, 28 September 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, notes that following a rise in the number of COVID-19 cases in the UK, UK Research and Innovation (UKRI) has decided to reinstate funding for the COVID-19 ACCORD clinical study in which … Read more
Bergen, Norge, 24. september 2020 – BerGenBio ASA (OSE: BGBIO), et biofarmasøytisk selskap i klinisk fase som utvikler nye, selektive hemmere av AXL-kinase for krefttyper med behov for forbedret behandlingstilbud, kunngjør at det har fått godkjenning fra REK (Regional Etisk Komité) i Norge for selskapets klinisk fase II-studie (BGBC020) for å vurdere effekten og sikkerheten … Read more
Bergen, Norway, 24 September 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that it has received approval from Norway’s Regional Ethics Committee (REK) for its company sponsored Phase II trial (BGBC020) to assess the efficacy and safety of bemcentinib for the treatment of … Read more
Bergen, Norway, 18 September 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that CEO Richard Godfrey will be presenting at the Sachs Annual Biotech in Europe Forum. Date and time: Wednesday 23 September at 1pm CET. Register for the event … Read more
Bergen, Norge, 11. september 2020 – BerGenBio ASA (OSE:BGBIO), et biofarmasøytisk selskap i klinisk fase som utvikler nye, selektive hemmere av AXL-kinase for krefttyper med behov for forbedret behandlingstilbud, kunngjør i dag at selskapet har mottatt regulatorisk godkjenning fra South African Health Products Regulatory Authority (SAHPRA) for å fortsette med selskapets klinisk fase II-studie for å … Read more
Bergen, Norway, 11 September 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that it has received regulatory approval from the South African Health Products Regulatory Authority (SAHPRA) to proceed with a company sponsored Phase II clinical trial to assess the efficacy and safety … Read more
Bergen, Norway, 1 September 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that a member of the senior management team will be presenting at the following virtual conferences: Solebury Trout Zoomside Chat, 1[st] September 1pm EDT (19:00 CEST)Live 1-2-1 interview … Read more
Bergen, Norway, 18 August 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need indications, announces its results for the second quarter and first half of 2020. A presentation and live webcast by BerGenBio’s senior management will take place at 10.00 am CET today, please see below … Read more
Primært effektendepunkt for total responsrate ble oppfylt i den fullt rekrutterte fase II-studien Bergen, 18. august 2020 – BerGenBio ASA (OSE: BGBIO), et biofarmasøytisk selskap i klinisk fase som utvikler nye, selektive hemmere av AXL-kinase for krefttyper med behov for forbedret behandlings tilbud, kunngjør at det primære endepunktet for den totale responsraten er oppfylt i … Read more
Primary endpoint of overall response rate was met in the fully recruited single arm phase II study Bergen, Norway,18 August 2020 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, announces that the primary endpoint of overall response rate has been met in the BERGAMO … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.